Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

40 results about "Novobiocin" patented technology

Novobiocin, also known as albamycin or cathomycin, is an aminocoumarin antibiotic that is produced by the actinomycete Streptomyces niveus, which has recently been identified as a subjective synonym for S. spheroides a member of the order Actinobacteria. Other aminocoumarin antibiotics include clorobiocin and coumermycin A1. Novobiocin was first reported in the mid-1950s (then called streptonivicin).

Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders

Novobiocin analogues and pharmaceutical composition containing such compounds useful for the treatment and / or prevention of neurodegenerative disorders and autoimmune disorders.
Owner:KANSAS UNIV OF

Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders

Novobiocin analogues and pharmaceutical composition containing such compounds useful for the treatment and / or prevention of neurodegenerative disorders and autoimmune disorders.
Owner:UNIVERSITY OF KANSAS

Novobiocin Analogues Having Modified Sugar Moieties

Novobiocin analogues useful as Hsp90 inhibitors in the treatment of cancer, neuroprotection, and autoimmune disorders.
Owner:UNIVERSITY OF KANSAS

Novobiocin analogues as anticancer agents

Novel analogues and derivatives of novobiocin are provided, including compounds having modifications to the amide side chain, coumarin ring, and sugar moieties. The compounds of the present invention are useful as heat shock protein 90 inhibitors, and may be used as anticancer and neuroprotective agents.
Owner:UNIVERSITY OF KANSAS +1

Recombinant viruses displaying a nonviral polypeptide on their external surface

We have made retrovirus particles displaying a functional antibody fragment. We fused the gene encoding an antibody fragment directed against a hapten with that encoding the viral envelope protein (Pr80env) of the ecotropic Moloney murine leukemia virus. The fusion gene was co-expressed in ecotropic retroviral packaging cells with a retroviral plasmid carrying the neomycin phosphotransferase gene (neo), and retroviral particles with specific hapten biding activities were recovered. Furthermore the hapten-binding particles were able to transfer the neo gene and the antibody-envelope fusion gene to mouse fibroblasts. In principle, the display of antibody fragments on the surface of recombinant retroviral particles could be used to target virus to cells for gene delivery, or to retain the virus in target tissues, or for the construction of libraries of viral display packages.
Owner:BIOFOCUS DICOVERY

Steroid derived antibiotics

InactiveUS20050032765A1Improve breathabilityLower the MICs of other antibioticsOrganic active ingredientsSteroidsBacteroidesNovobiocin
A series of novel steroid derivatives are described. The steroid derivatives are antibacterial agents. The steroid derivatives also act to sensitize bacteria to other antibiotics including erythromycin and novobiocin.
Owner:BRIGHAM YOUNG UNIV

Novobiocin analogues having modified sugar moieties

The disclosure provides novobiocin analogues with noviose replacements which are useful as Hsp90 inhibitors in the treatment of cancer.
Owner:UNIVERSITY OF KANSAS

Novobiocin analogues and treatment of polycystic kidney disease

InactiveUS20110082098A1Reduction of cyst formationBiocideCarbohydrate active ingredientsNovobiocinCyst formation
Novobiocin analogues are useful in methods of treating, inhibiting, and / or preventing cyst formation in autosomal dominant polycystic kidney disease (ADPKD) in a subject. The disclosure provides methods of treating ADPKD comprising administering a therapeutically effective amount of a coumarin-3-carboxamide novobiocin analogue. Accordingly, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of mTOR pathway phosphoproteins P-mTOR, P-Akt and P-S6K, or combinations thereof. Further, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of Hsp-90 client proteins CFTR, ErbB2, c-Raf and Cdk4, or combinations thereof.
Owner:UNIVERSITY OF KANSAS

Attenuated Live Vaccines for Aquatic Animals

InactiveUS20120258139A1Preventing and reducing enteric septicemiaPreventing and reducing streptococcal diseaseAntibacterial agentsBacterial antigen ingredientsNovobiocinBacteroides
Safe and effective live vaccines against bacteria infecting aquatic animals were created through the induction of novobiocin-resistance in liquid culture and novobiocin- and rifampicin-resistance in liquid culture.
Owner:US SEC AGRI

Application of benzo Alpha-pyrone compound as Gamma-type human herpes virus-resistant medicine

The invention discloses an application of a benzo Alpha-pyrone compound as a Gamma-type human herpes virus-resistant medicine. According to the invention, the compound resistant to Gamma-type human herpes virus infection is higher in activity as compared with a novobiocin which is a marketed medicine, and is less in toxicity based on a cytoxicity test. The compound can be used for curing or preventing related diseases caused by KSHV infection.
Owner:SUN YAT SEN UNIV

Coloring culture medium for detecting food-borne pathogenic Yersinia

The present invention discloses a coloring culture medium for detecting food-borne pathogenic Yersinia, wherein the culture medium contains soybean peptone, yeast powder, sodium chloride, sodium oxalate, agar, a beta-riboside chromogenic substrate, a beta-galactoside chromogenic substrate, esculin, ammonium ferric citrate, bile salt No.3, cephalosporin, novobiocin, and the balance of water. According to the present invention, the coloring culture medium has characteristics of simple formula and convenient preparation operation, can be used for the separation and the detection of food-borne pathogenic Yersinia, and further has advantages of specificity, high efficiency, rapidness, low cost, simple result determination, wide application prospect, and the like.
Owner:BEIJING JUNLIKANG BIOTECHNOLOGY CO LTD

Eucommia ulmoides lignans and application of Eucommia ulmoides in preparation of Hsp90alpha inhibitor and anti-tumor drug

The invention discloses an eucommia ulmoides lignans and an application of eucommia ulmoides in preparation of Hsp90alpha inhibitor and anti-tumor drug, in particular to the application in preparationof heat shock protein 90 alpha (Hsp 90 alpha) selective C-terminal inbhibitor and use in preventing breast cancer and prostate cancer. The invention finds that the eucommia ulmoides lignans and its extractive extracted and prepared by using eucommia ulmoides as raw material can inhibit enzymatic activity of recombined human heat shock protein 90 alpha-C terminal; compared with a positive controldrug novobiocin, the eucommia ulmoides lignans show more excellent anti-cancer activity.
Owner:CENT SOUTH UNIV

Chromogenic medium and detection sheet capable of simultaneously detecting coliform and salmonella

The invention discloses a chromogenic medium and a chromogenic detection sheet capable of simultaneously detecting coliform and salmonella. The chromogenic medium contains peptone, yeast extract powder, beef extract powder, sodium chloride, sodium pyruvate, cholate, a specific enzyme chromogenic substrate, an enzyme inducer, a stabilizer, novobiocin and high molecular water-absorbent gel. The chromogenic medium is used for simultaneously detecting the coliform and the salmonella, is high in detection sensitivity, short in detection time and high in efficiency, and can simultaneously perform qualitative detection and quantitative detection and analysis on the coliforms and the salmonella, so that experimental operation is significantly reduced and the cost is saved; the chromogenic medium can be applied to direct sampling detection on tableware, food producing environment and equipment detection and other places; the coliform shows blue bacterial spots, and the salmonella shows red bacterial spots.
Owner:GUANGZHOU JUBIOS BIOTECH CO LTD

Salmonella detection method and culture medium for detection

ActiveCN103898191AShorten the timeSave the follow-up separation and identification processMicrobiological testing/measurementAgainst vector-borne diseasesPre enrichmentNovobiocin
The invention discloses a salmonella detection method, which carries out detection by using a capillary tube method. An MSTT culture medium is filled in a capillary tube, and per 1L of the culture medium, comprises the following components: 5.0-10.0 g of peptone, 0-5.0 g of a beef extract, 0-3.0 g of sodium chloride, 1.0-5.0 g of bile salts, 30.0-50.0 g of sodium thiosulfate, 9-10 mg of brilliant green, 4.0-5.0 g of iodine, 5.0-6.0 g of potassium iodide, 2.5-3.0 g of agar, 0 or 20-40 mg of novobiocin, and the balance of water. According to the invention, the capillary tube culture method and the MSTT culture medium are adopted for detecting salmonella, and salmonella pre-enrichment and enrichment steps are merged, so that a lot of time is saved, and the detection time is reduced by at least 24 h; and samples are subjected to preliminary screening by using a capillary tube culture method, so that a lot of subsequent separation and identification processes are saved.
Owner:济南市疾病预防控制中心

Use of geldanamycin and related compounds for treatment of fibrogenic disorders

A method for prophylaxis or treatment of a mammal, particularly human, at risk for a fibrogenic disorder is disclosed. The compositions and methods of the invention are directed both to treatments for existing fibrogenic disorders and prevention thereof. Such disorders include, but are not limited to, connective tissue diseases, such as scleroderma (or systemic sclerosis), polymyositis, systemic lupus erythematosis and rheumatoid arthristis, and other fibrotic disorders, including liver cirrhosis, keloid formation, interstitial nephritis and pulmonary fibrosis. A therapeutic composition according to the invention includes, as a therapeutic agent, an inhibitor of a collagen promoter in a pharmaceutically acceptable inert carrier vehicle, preferably for local, and particularly topical, application. Exemplary inhibitors include those that interfere with heat shock protein 90 (Hsp 90) chaperone function, e.g., the specific inhibitor geldanamycin or other known Hsp90 inhibitors such as macbecin I and II, herbimycin, radcicol and novobiocin.
Owner:TRUSTEES OF BOSTON UNIV

C-terminal hsp90 inhibitors to treat pituitary adenomas

The present invention relates to C-terminal HSP90 inhibitors, like silibinin, novobiocin and derivatives thereof, stereoisomeric forms, prodrugs, solvates, hydrates and / or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and / or diluents. Said compounds and its compositions have been identified as useful for the treatment of pituitary adenomas such as corticotroph adenomas, lactotroph adenomas, somatotroph adenomas and thyrotroph adenomas.
Owner:MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN EV

Construction method for single knock-out mutant bacterial strain producing deoxynivalenol in high-yield mode

A construction method for a single knock-out mutant bacterial strain producing deoxynivalenol in a high-yield mode includes the following steps of firstly, knocking a negative regulatory factor high-affinity phosphodiesterase gene FgPDE2 generated in the fusarium graminearumout deoxynivalenol synthesis process out of a genome of fusarium graminearum PH-1 through a split-PCR method, and obtaining the single knock-out mutant, wherein the gene FgPDE2 and upstream and downstream sequences are shown in SEQ ID NO:1; secondly, PEG-mediated protoplast is converted into fusarium graminearum, knocking out converters through resistance screening and marker screening, and verifying that the target gene knocking out the converters is replaced with a neomycin resistance gene through primers 5F and 6R with the genome of fusarium graminearum serving as the reference. The toxicity production amount of the single knock-out mutant bacterial strain is greatly increased; the toxicity production amount of a double knock-out mutant bacterial strain is higher; the gene modification mutant loses the capacity for infecting wheatears, and negative effects caused by possible diffusion of the double knock-out mutant bacterial strain are greatly reduced.
Owner:NORTHWEST A & F UNIV

Coumermycin/novobiocin-regulated gene expression system

ActiveUS20070026486A1Rapid on/off switching of gene expressionAntibacterial agentsOrganic active ingredientsNovobiocinOperon
A chimeric transactivator comprises a transcription activation domain, a repressor protein DNA binding domain and the bacterial DNA gyrase B subunit. A target gene is operatively linked to operator DNA sequences recognized by the repressor binding domain. The addition of the antibiotic coumermycin results in a coumermycin-switched dimerization of the transactivator, which then binds to operator DNA sequences and activates transcription of the target gene. The addition of novobiocin switches off expression of the target gene by abolishing coumermycin-induced dimerization of the transactivator.
Owner:NAT RES COUNCIL OF CANADA

Application of novobiocin in preparation of drug with function of inhibiting TRPV1 (transient receptor potential cation channel, subfamily V, member 1) expression and transfer

The invention relates to an application of novobiocin in preparation of a drug with a function of inhibiting TRPV1 (transient receptor potential cation channel, subfamily V, member 1) expression and transfer. With overexpression TRPV1 cells and mice taken as study models, it is found that 5-50 mu M novobiocin can inhibit the penetration amount of capsaicin passing by intestinal mucosa in a concentration-dependent manner and also can have an inhibition function on TRPV1 protein and mRNA expression on rat intestinal mucosa tissue. In the overexpression TRPV1 cell penetration model, the novobiocin also reduces the TRPV1 expression capability in a concentration-dependent manner and reduces the accumulation function of capsaicin in overexpression cells. In an in-vivo experiment, the inhibitionfunction of the novobiocin on TRPV1 is definitely confirmed. The novobiocin is a novel TRPV1 inhibitor, the pharmacologic action of the novobiocin for inhibiting TRPV1 expression is found for the first time, and the novobiocin can also affect the transfer capability of a TRPV1 channel.
Owner:NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV

Model animals non-responsive to mycobacteria-origin lipoprotein/lipopeptide

The present invention is to provide TLR1 knockout mice specifically recognizing mycobacterial lipoproteins / lipopeptides, being useful to clarify the role of TLR1 in vivo, or a method for screening substances promoting or suppressing the response to mycobacterial lipoproteins / lipopeptides by using the same. TLR1 genes are separated from murine genomic library, the genomic part containing the intracellular and transmembrane domain of the TLR1 gene is replaced with a neomycin resistant gene, HSV-tk gene being gene encoding thymidine kinase into 3′ end is introduced, ES cell clones having double resistance to G418 and Gancyclovir are screened, and ES cell clones are injected into the blastocyst of C57BL / 6 mice, to generate TLR1 knockout mice through the germline.
Owner:JAPAN SCI & TECH CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products